Latest "irbesartan amlodipine irbesartan Hypertension" News Stories

20:27 EDT 30th April 2016 | BioPortfolio

Here are the most relevant search results for "irbesartan amlodipine irbesartan Hypertension" found in our extensive news archives from over 250 global news sources.

More Information about irbesartan amlodipine irbesartan Hypertension on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about irbesartan amlodipine irbesartan Hypertension for you to read. Along with our medical data and news we also list irbesartan amlodipine irbesartan Hypertension Clinical Trials, which are updated daily. BioPortfolio also has a large database of irbesartan amlodipine irbesartan Hypertension Companies for you to search.

Showing "irbesartan amlodipine irbesartan Hypertension" News Articles 1–25 of 937

Extremely Relevant

Angiotensin II receptor blocker irbesartan attenuates cardiac dysfunction induced by myocardial infarction in the presence of renal failure

Dimerix to continue supplying propagermanium to kidney disease patients

The TGA’s special access scheme has granted clinical-stage biotech company Dimerix (ASX:DXB) the right to continue supplying propagermanium to participants in its DMX-200 clinical trial, upon clinician approval and participant agreement. DMX-200 is a combination of two existing drugs: a chemokine receptor CCR2 blocker (propagermanium) used for its anti-inflammatory properties and not on the Aus...


Dimerix Receives TGA Special Access Scheme Approval to Continue to Supply Propagermanium to Kidney Patients on its DMX-200 Phase II trial

Melbourne, Australia, 19 April 2016: Dimerix Limited (ASX: DXB), a clinical-stage biotechnology company committed to discovering and developing new therapeutic treatments identified using its proprietary screening assay, today announced that the Therapeutic Goods Administration in Australia (TGA) has confirmed that Dimerix can continue to supply propagermanium to participants in the DMX-200 clin...

Pulmonary Hypertension Association (PHA) Names ‘Periwinkle Pioneers’: Honor Recognizes 25 Years of Pulmonary Hypertension (PH) Advancements

Silver Spring, Md (PRWEB) November 25, 2015 In honor of Pulmonary Hypertension Awareness Month, the Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension (PH) patients and helping t...

Celecoxib/amlodipine besylate: Phase III data

Pulmonary Hypertension Association Launches “PH Care for All” to Investigate and Address Pulmonary Hypertension Treatment Disparities

Silver Spring, Md. (PRWEB) April 21, 2016 While the Pulmonary Hypertension Association (PHA) has seen marked progress in the treatment of pulmonary hypertension (PH) in its 25-year history, all things are not equal in the advancement of patient care. PHA has assembled 26 esteemed pulmonary hy...

Media Advisory: Results of New Research in High Blood Pressure Management Expected Today

MARKHAM, ONTARIO -- (Marketwired) -- 11/09/15 -- Results from the National Heart, Lung and Blood Institute (NHLBI) Systolic Blood Pressure Intervention Trial (SPRINT) will be presented at the American Heart Association's annual scientific meeting in Orlando, Florida this afternoon. SPRINT studied the results of controlling systolic blood pressure to a target of less than 120 millimeters of mercu...

A General Cardiologist's Approach to Managing Hypertension

Dr Henry Black interviews Dr John Bisognano and discusses his approach to managing hypertension and treating resistant hypertension. Medscape Cardiology

Treating hypertension in patients with medical comorbidities

What you need to knowTwo out of three people with hypertension have a comorbidityThere is NICE guidance on blood pressure targets and drug therapy for patients with hypertension and comorbidities...

Celecoxib/amlodipine besylate: Completed Phase III enrollment

Untreated hypertension increases risk for intracerebral hemorrhage

The risk for intracerebral hemorrhage is more than nine times higher for men and women with untreated hypertension compared with those with treated hypertension, researchers reported at the International Stroke Conference.Treatment of hypertension appears to have a substantial impact on risk for intracerebral hemorrhage, according to Kyle Walsh, MD, assistant professor of emergency medicine at Uni...

Hypertension in 2015: Resistant hypertension: impact and evolving treatment options

Combination therapy with optimal doses of multiple antihypertensive drugs fails to achieve blood pressure (BP) control in up to 15% of hypertensive patients. Key studies in 2015 highlighted the risks of uncontrolled hypertension and evaluated new therapeutic modalities designed to achieve satisfactory BP control in patients with treatment-resistant hypertension.

Novartis launches new hypertension program in Ghana

The Novartis Foundation and its partners have begun screening patients in a Community-based Hypertension Improvement Project (ComHIP) in Ghana in a two-year program designed to evaluate the impact of an innovative healthcare model on hypertension management and control. With the new healthcare model, Novartis and its partners aim to evaluate the impact of innovative healthcare and improve the cont...

Hypertension: Benefits of strict blood-pressure lowering in hypertension

A new meta-analysis by Ettehad and colleagues, which included >613,000 patients with hypertension from randomized, controlled trials, clearly demonstrates that antihypertensive medication reduces cardiovascular events and death in all patients, including those with systolic blood pressure

New Guidelines Focus on Pulmonary Hypertension in Kids

TUESDAY, Nov. 3, 2015 -- The first guidelines for diagnosis and treatment of pulmonary hypertension in children have been released by the American Heart Association and the American Thoracic Society. Pulmonary hypertension is a sometimes fatal...

Kitov Pharmaceuticals Reports Additional Data from its Phase III Trial on the Beneficial Blood Pressure Effects of KIT-302

TEL AVIV, Israel, Dec. 17, 2015 /PRNewswire/ -- Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced more data from its successfully concluded Phase III trial for its lead drug candidate, KIT-302. Data showed the favorable blood pressure effects of KIT-302 were present in all blood pressure variables measured in ...

Severe uncontrolled hypertension contraindicated with Betmiga

Severe uncontrolled hypertension is now listed as a contraindication in the summary of product characteristics for Betmiga (mirabegron; Astellas). Blood pressure should be measured before starting treatment and monitored regularly during treatment, especially in patients with hypertension.

Hypertension: When should we treat hypertension in patients with diabetes?

Diabetes mellitus and hypertension are closely related, and guidelines have recommended aggressive treatment of hypertension in patients with diabetes. However, no single clinical trial is conclusive. An extensive review of the use of blood-pressure-lowering drugs in patients with diabetes supports treating blood pressure >140/90 mmHg, whereas reducing blood pressure in people with normal or high...

From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency

Risk of Renal, CV and Mortality Outcomes in Hypertension

Which hidden risks are the most likely to be lurking for patients with hypertension? Kidney International

Clinical factors associated with readmission for postpartum hypertension in women with pregnancy-related hypertension: a nested case control study

Changes in BMI and Risk for Hypertension During Childhood and Adolescence

During a 3-year follow-up study, the riskiest “change” associated with developing hypertension was remaining obese.

Hypertension: Oxidative stress and immune activation in hypertension

Hypertension: IL-1 receptor-induced sodium reabsorption in hypertension

Prevalence and determinants of resistant hypertension in a sample of patients followed in Italian hypertension centers: results from the MINISAL-SIIA study program

Quick Search

News Quicklinks